Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge.

Harro C, Louis Bourgeois A, Sack D, Walker R, DeNearing B, Brubaker J, Maier N, Fix A, Dally L, Chakraborty S, Clements JD, Saunders I, Darsley MJ.

Vaccine. 2019 Mar 28;37(14):1978-1986. doi: 10.1016/j.vaccine.2019.02.025. Epub 2019 Feb 21.

2.

Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development.

Chakraborty S, Randall A, Vickers TJ, Molina D, Harro CD, DeNearing B, Brubaker J, Sack DA, Bourgeois AL, Felgner PL, Liang X, Mani S, Wenzel H, Townsend RR, Gilmore PE, Darsley MJ, Rasko DA, Fleckenstein JM.

J Infect Dis. 2018 Sep 22;218(9):1436-1446. doi: 10.1093/infdis/jiy312.

PMID:
29800314
3.

An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli.

Porter CK, Riddle MS, Alcala AN, Sack DA, Harro C, Chakraborty S, Gutierrez RL, Savarino SJ, Darsley M, McKenzie R, DeNearing B, Steinsland H, Tribble DR, Bourgeois AL.

PLoS One. 2016 Mar 3;11(3):e0149358. doi: 10.1371/journal.pone.0149358. eCollection 2016.

4.

Development of a fast-dissolving tablet formulation of a live attenuated enterotoxigenic E. coli vaccine candidate.

Lal M, Priddy S, Bourgeois L, Walker R, Pebley W, Brown J, Desai J, Darsley MJ, Kristensen D, Chen D.

Vaccine. 2013 Oct 1;31(42):4759-64. doi: 10.1016/j.vaccine.2013.08.010. Epub 2013 Aug 17.

PMID:
23965220
5.

The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.

Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD.

Clin Vaccine Immunol. 2012 Dec;19(12):1921-31. doi: 10.1128/CVI.00364-12. Epub 2012 Oct 3.

6.

Generation and characterization of a live attenuated enterotoxigenic Escherichia coli combination vaccine expressing six colonization factors and heat-labile toxin subunit B.

Turner AK, Stephens JC, Beavis JC, Greenwood J, Gewert C, Randall R, Freeman D, Darsley MJ.

Clin Vaccine Immunol. 2011 Dec;18(12):2128-35. doi: 10.1128/CVI.05345-11. Epub 2011 Oct 12.

7.

A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.

Harro C, Sack D, Bourgeois AL, Walker R, DeNearing B, Feller A, Chakraborty S, Buchwaldt C, Darsley MJ.

Clin Vaccine Immunol. 2011 Dec;18(12):2118-27. doi: 10.1128/CVI.05342-11. Epub 2011 Oct 12.

8.

Caught in the act: in vivo development of macrolide resistance to Campylobacter jejuni infection.

Lindow JC, Poly F, Tribble DR, Guerry P, Carmolli MP, Baqar S, Porter CK, Pierce KK, Darsley MJ, Sadigh KS, Dill EA; Campylobacter Study Team, Kirkpatrick BD.

J Clin Microbiol. 2010 Aug;48(8):3012-5. doi: 10.1128/JCM.00768-10. Epub 2010 Jun 16.

9.

Recrudescent Campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well-characterized organism.

Baqar S, Tribble DR, Carmolli M, Sadigh K, Poly F, Porter C, Larsson CJ, Pierce KK, Guerry P; Campylobacter Study Team, Darsley M, Kirkpatrick B.

Clin Vaccine Immunol. 2010 Jan;17(1):80-6. doi: 10.1128/CVI.00252-09. Epub 2009 Nov 18.

10.

Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects.

Tribble DR, Baqar S, Carmolli MP, Porter C, Pierce KK, Sadigh K, Guerry P, Larsson CJ, Rockabrand D, Ventone CH, Poly F, Lyon CE, Dakdouk S, Fingar A, Gilliland T, Daunais P, Jones E, Rymarchyk S, Huston C, Darsley M, Kirkpatrick BD.

Clin Infect Dis. 2009 Nov 15;49(10):1512-9. doi: 10.1086/644622.

PMID:
19842970
11.

Characterization of two Campylobacter jejuni strains for use in volunteer experimental-infection studies.

Poly F, Read TD, Chen YH, Monteiro MA, Serichantalergs O, Pootong P, Bodhidatta L, Mason CJ, Rockabrand D, Baqar S, Porter CK, Tribble D, Darsley M, Guerry P.

Infect Immun. 2008 Dec;76(12):5655-67. doi: 10.1128/IAI.00780-08. Epub 2008 Sep 22.

12.

A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC.

McKenzie R, Darsley M, Thomas N, Randall R, Carpenter C, Forbes E, Finucane M, Sack RB, Hall E, Bourgeois AL.

Vaccine. 2008 Aug 26;26(36):4731-9. doi: 10.1016/j.vaccine.2008.06.064. Epub 2008 Jul 9.

PMID:
18602960
13.

Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation.

Daley A, Randall R, Darsley M, Choudhry N, Thomas N, Sanderson IR, Croft NM, Kelly P.

Gut. 2007 Nov;56(11):1550-6. Epub 2007 Jun 12.

15.

Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.

Turner AK, Beavis JC, Stephens JC, Greenwood J, Gewert C, Thomas N, Deary A, Casula G, Daley A, Kelly P, Randall R, Darsley MJ.

Infect Immun. 2006 Feb;74(2):1062-71.

16.

Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.

McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA.

Infect Immun. 2006 Feb;74(2):994-1000.

17.

Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.

Carpenter CM, Hall ER, Randall R, McKenzie R, Cassels F, Diaz N, Thomas N, Bedford P, Darsley M, Gewert C, Howard C, Sack RB, Sack DA, Chang HS, Gomes G, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3709-18. Epub 2005 Jul 26.

PMID:
16153753
18.

Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen.

Londoño-Arcila P, Freeman D, Kleanthous H, O'Dowd AM, Lewis S, Turner AK, Rees EL, Tibbitts TJ, Greenwood J, Monath TP, Darsley MJ.

Infect Immun. 2002 Sep;70(9):5096-106.

19.

Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans.

Turner AK, Terry TD, Sack DA, Londoño-Arcila P, Darsley MJ.

Infect Immun. 2001 Aug;69(8):4969-79. Erratum in: Infect Immun 2001 Oct;69(10):6564.

20.

Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2.

Grabowska AM, Jennings R, Laing P, Darsley M, Jameson CL, Swift L, Irving WL.

Virology. 2000 Mar 30;269(1):47-53.

21.

Determination of binding constants of diabodies directed against prostate-specific antigen using electrochemiluminescence-based immunoassays.

Abraham R, Buxbaum S, Link J, Smith R, Venti C, Darsley M.

J Mol Recognit. 1996 Sep-Dec;9(5-6):456-61.

PMID:
9174923
22.

Screening and kinetic analysis of recombinant anti-CEA antibody fragments.

Abraham R, Buxbaum S, Link J, Smith R, Venti C, Darsley M.

J Immunol Methods. 1995 Jun 14;183(1):119-25.

PMID:
7602129
23.

Spectrophotometric quantitation of silver in X-ray film images and silver-stained electrophoresis gel bands.

Sanchez RI, Darsley MJ, Martin MT.

Anal Biochem. 1995 Jan 1;224(1):190-4.

PMID:
7710070
24.

Aspects of antibody-catalyzed primary amide hydrolysis.

Titmas RC, Angeles TS, Sugasawara R, Aman N, Darsley MJ, Blackburn G, Martin MT.

Appl Biochem Biotechnol. 1994 May-Jun;47(2-3):277-90; discussion 291-2.

PMID:
7944343
25.

Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine.

Abraham R, Aman N, von Borstel R, Darsley M, Kamireddy B, Kenten J, Morris G, Titmas R.

Cell Biophys. 1994;24-25:127-33.

PMID:
7736516
26.

Isoabzymes: structurally and mechanistically similar catalytic antibodies from the same immunization.

Angeles TS, Smith RG, Darsley MJ, Sugasawara R, Sanchez RI, Kenten J, Schultz PG, Martin MT.

Biochemistry. 1993 Nov 16;32(45):12128-35.

PMID:
8218291
27.

Cytotoxic T lymphocyte recognition of hybrid MHC class I molecules.

Kanda T, Macchi MJ, LaPan K, Darsley M, Appella E, Frelinger JA.

J Immunogenet. 1988 Oct-Dec;15(5-6):295-305.

PMID:
2475544
28.

Interaction of an immunodominant epitope with Ia molecules in T-cell activation.

Adorini L, Sette A, Buus S, Grey HM, Darsley M, Lehmann PV, Doria G, Nagy ZA, Appella E.

Proc Natl Acad Sci U S A. 1988 Jul;85(14):5181-5.

29.
31.

Supplemental Content

Loading ...
Support Center